ArticleCancer medicine2026
TTK Overexpression: A Negative Prognostic Biomarker in Anaplastic Thyroid Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGiven threonine and tyrosine kinase (TTK)'s oncogenic role in various cancers and its understudied status in thyroid cancer, this study investigates TTK expression in thyroid lesions to assess its diagnostic and therapeutic potential.
methodsWe analyzed differential TTK expression levels using public datasets (n = 143) and clinical samples (n = 91) across various thyroid lesions. Prognostic predictions based on TTK expression were conducted using a 2 × 2 contingency table, receiver operating characteristic curve (ROC), and Kaplan-Meier survival analysis.
resultsTTK expression levels increased with the malignancy grade of thyroid lesions. In highly malignant anaplastic thyroid carcinoma (ATC) tissue, both TTK mRNA (p = 0.003) and protein levels (p = 0.000) were significantly higher than those in less malignant papillary thyroid carcinoma (PTC). TTK protein expression showed excellent discrimination between benign and malignant thyroid lesions (AUC = 0.983-0.999, p = 0.000). Notably, ATC patients with high TTK protein expression had significantly lower overall survival rates compared to those with low expression, effectively predicting prognosis (AUC = 0.833, p = 0.046).
conclusionTTK expression is markedly upregulated in highly malignant ATC tissues compared to benign lesions and PTC. The protein level of TTK emerges as a valuable diagnostic marker for distinguishing between benign and malignant thyroid conditions and serves as a crucial prognostic indicator for ATC. Further exploration and validation of its application in clinical practice are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.